New Release – Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial
April 2, 2024
Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device
Read More
New Release – Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors
März 26, 2024
Financing and Reinforcement of Board of Directors Builds Momentum in Readiness for the Initiation of the IDE Pivotal Trial
Read More
New Release – Final data from European PROTEMBO C Trial Published in EuroIntervention Journal
März 5, 2024
New published European clinical evidence builds momentum for the FDA approved Pivotal PROTEMBO clinical trial.
Read More
New Release – Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study
Oktober 23, 2023
Novel Adaptive Superiority Trial Design of ProtEmbo® Cerebral Embolic Protection (CEP) System
Read More
News Release – Professor J Mocco to Join Protembis’ Board of Directors
August 29, 2023
Protembis announces the appointment of Professor J. Mocco to Board of Directors
Read More
News Release – Azin Parhizgar As New Chairwoman of Protembis
September 15, 2022
Azin Parhizgar To Chair Protembis’ New Board of Directors
Read More
News Release – EU Clinical Study
Februar 25, 2021
Protembis announces completion of 20 cases in European CE mark study with the ProtEmbo® Cerebral Protection System Enrollment with advanced...
Read More
News Release – Series A Financing
Oktober 18, 2018
Aachen-based Startup Company Protembis Successfully Closes $ 10 Million Series A Financing
Read More
News Release – ISO 13485:2016
Januar 9, 2018
Protembis Achieves ISO 13485:2016 Quality Management System Certification
Read More